<DOC>
	<DOCNO>NCT00506909</DOCNO>
	<brief_summary>The objective study compare efficacy intranasal oxytocin versus intranasal placebo improve symptom schizophrenia patient residual symptom despite adequate treatment antipsychotic medication .</brief_summary>
	<brief_title>Oxytocin Add Study Stable Schizophrenic Patients</brief_title>
	<detailed_description>Schizophrenia patient treat even best currently available antipsychotic drug continue experience significant symptom . There strong need well treatment include treatment safely give adjunct current antipsychotic order improve overall efficacy treatment . Oxytocin neurohypophyseal peptide best know role neurohormone involve parturition lactation . In addition well establish peripheral effect , compel body converge evidence indicate oxytocin play critical role regulation number diverse centrally-mediated behavioral cognitive process highly relevant Schizophrenia , include social attachment memory , ( see Argiolas Gessa 1990 ; McCarthy Aaltemus 1997 ) .Furthermore , several line research suggest oxytocin receptor may important target development novel treatment schizophrenia . Oxytocin receptor exist several area brain heavily implicated pathophysiology schizophrenia , nucleus accumbens hippocampus , ( Van Leeuwan et al 1985 ) . Oxytocin administer peripherally inhibits dopamine transmission mesolimbic pathway ( Sarnyai 1992 ) et al , 1990 ) . Antipsychotics find elevate secretion oxytocin rat ( Uvnas-Moberg et al 1992a ) suggest endogenous oxytocin may play role therapeutic effect antipsychotic drug . Each subject enrol 6 week treatment period screen phase Study procedure involve weekly clinic visit outpatient . Forty patient randomly assign either 40 IU oxytocin twice daily vehicle placebo . After 3 week , treatment cross subject receive oxytocin receive placebo vice versa . The study ratio 1:1 . Dose oxytocin base upon previous study human show improvement schizophrenia relate change behavior brain function ( Kosfeld et al , 2005 ; Kirsch 2005 ; Heinrich M 2003 ) . The total study duration individual subject approximately 7 week , include 7-day screening period , baseline ( randomization ) visit , three week treatment period , 1 week washout , baseline , three week cross treatment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Adult men woman , 18 year age old . 2 . Meet DSMIV criterion Schizophrenia . 3 . Women childbearing potential must test negative pregnancy time enrollment base urine pregnancy test agree use reliable method birth control study . 4 . Must therapeutic dose atypical antipsychotic medication ( example limit Clozapine Olanzapine , Risperidone , Ziprasidone , Aripiprazole , Seroquel ) major dose change least 4 week . 5 . A minimum PANSS total score 55 screen baseline score least 4 ( moderate ) subscale PANSS ( suspiciousness/persecution ) screening . 6 . Have Clinical Global ImpressionsSeverity ( CGIS ) scale score least 4 ( moderately ill ) baseline . 7 . Must able communicate effectively investigator study coordinator ability provide inform consent . 8 . Must able use nasal spray . 9 . Must demonstrate acceptable degree compliance medication procedure opinion investigator . Subjects exclude study meet follow criterion : 1 . Are pregnant breastfeeding ( negative pregnancy test screening ) . 2 . A urine drug screen perform screen must show evidence recent use drug abuse . 3 . Any active medical condition opinion investigator interfere objective study . 4 . Are unsuitable way participate study , opinion investigator . 5 . Another current DSMIV diagnosis Schizophrenia . Permitted : Subjects one SSRI , and/or sleep medication ( diphenhydramine , zolpidem , zaleplon , diazepam ) , reasonable dose , judge investigator , permit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>oxytocin</keyword>
</DOC>